TNFSF10
Reaktivität: Human
WB
Wirt: Maus
Polyclonal
unconjugated
Applikationshinweise
ELISA: In a Sandwich ELISA (assuming 100 μL/well), a concentration of 1-2 μg/mL of thisantibody will detect at least 0.2 ng/well of recombinant Human TRAIL/APO-II when usedwith Biotin conjugated anti-Human TRAIL/APO-II (cat. PP1084B) as the detection antibody. Western Blot: To detect Human TRAIL/Apo2L by Western Blot analysis this antibody can beused at a concentration of 0.25-0.50 μg/mL. Used in conjunction with compatiblesecondary reagents the detection limit for recombinant Human TRAIL/Apo2L is 0.25-1.0 ng/lane, under reducing or non-reducing conditions. Neutralization: To yield one-half maximal inhibition [ND50] of the biological activity ofHuman TRAIL/Apo2L (10.0 ng/mL), a concentration of 0.30-0.60 μg/mL of this antibody isrequired. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Rekonstitution
Restore in sterile water to a concentration of 1.0 mg/mL.
Konzentration
1.0 mg/mL
Buffer
PBS without preservatives.
Konservierungsmittel
Without preservative
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody prior to reconstitution at -20 °C. Following reconstitution the antibody can be stored at 2-8 °C for one month or at -20 °C for longer.
Target
TRAIL (TNFSF10)
(Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))
Apoptosis or programmed cell death is induced in cells by a group of death domain containing receptors. Binding of ligand to these receptors sends signals that activate members of the caspase family of proteases. The signals ultimately cause degradation of chromosomal DNA by activating DNase. TRAIL (TNF related apoptosis induced ligand) or Apo 2L initiates apoptosis of tumor cells by binding to either of its receptors, DR4 or DR5. These receptors consist of an extracellular TRAIL binding domain and a cytoplasmic "death domain". In addition, two decoy receptors for TRAIL have also been identified. These receptors, designated DcR1 and DcR2, lack the death domain. Binding of TRAIL to either of these receptors, therefore, does not transmit the death signal. Thus, these receptors represent a novel way of regulating cell sensitivity to a pro-apoptotic cytokine at the cell surface. TRAIL is expressed predominantly in spleen, lung, and prostate but also in many other tissues.Synonyms: APO2L, Apo-2 ligand, Apo-2L, TNF-related apoptosis-inducing ligand, TNFSF10, Tumor necrosis factor ligand superfamily member 10